Human polyclonal immunoglobulins for intravenous use and transplantation;Immunoglobulines polyclonales intraveineuses (IVIg): Quel interet en transplantation?

Nephrologie

Volumn 20, Issue 3, 1999, Pages 139-143

  Haymann, J Ph ^a   Glotz, D ^b  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Anti HLA antibodies; IVIg; Transplantation

Indexed keywords

IMMUNOGLOBULIN G;

ANTIBODY TITER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; REVIEW; SUBSTITUTION THERAPY;

ANTIBODIES, ANTI-IDIOTYPIC; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 0032993064     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Lundblad JL, Londeree N. The effect of processing methods on intravenous immune globulin preparations. J Hosp Infection 1988; 12: 3-15.
2. Nielsen H. Immunoglobulin preparations for intravenous administration. A review of their biologic activities and comparison of various preparation methods. Allergy 1994; 49: 69-73.
3. Blasczyk R, Westhoff U, Grossewilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-90.
4. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-16.
5. Glotz D, Haymann JP, Sansonetti N, François A, Menoyo-Calonge V, Bariety J, Druet P. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins(IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335-7.
6. Duhem C, Dicato MA, Ries F. Side-effect of intravenous immune globulins. Clin Exp Immunol 1994; 97: 79-83.
7. Kazatchkine MD. In Immunoglobulins: Extending the horizons (ed. Publ., P.) London, 1994; 1-12.
8. Reed E, Macmanus P, Ho E, Benvenisty A, Hardy M, Brensilver J, King DW, Suciu-foca N. Prediction of humoral immune responses to HLA through anti-idiotypic antibody studies. Transplant Proc 1989; 21: 708-10.
9. Taube DH, Williams DG, Cameron JS, Bewick M, Ogg CS, Rudge CJ, Welsh KI, Kennedy LA, Thick MG. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984; i: 824-6.
10. Hiesse C, Kriaa F, Rousseau P, Farahmand H, Bismuth A, Fries D, Charpentier B. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant 1992; 7: 944-51.
11. Reed E, Hardy M, Benvenisty A, Lattes C, Brensilver J, McCabe R, Reemstma K, King DW, Suciu-Foca N. Effect of anti-idiotypic antibodies to HLA on graft survival in renal-allograft recipients. N Engl J Med 1987; 316: 1450-5
12. Glotz D, Sansonnetti N, Francois A, Menoyo-Calonge V, Haymann JP. In vitro inhibition of anti-HLA antibodies by human polyclonal immunoglobulins. J Amer Soc Nephrol 1990; (abstract) 1: 749.
13. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553-62.
14. Haymann JP, Glotz D, Sansonnetti N, Francois A, Bariéty J, Druet P. Normal human polyclonal immunoglobulins for intravenous use (IVIg) contain anti-idiotypes directed against human anti-HLA antibodies. J Amer Soc Nephrol 1993; (abstract) 4: 939.
15. Glotz D, Haymann JP, Niaudet P, Lang P, Druet P, Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27: 1038-9.
16. McIntyre JA, Higgins N, Britton R, Faucett S, Johnson S, Beckman D, Hormuth D, Fehrenbacher J, Halbrook H. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Transplantation 1996; 62: 691-3.
17. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865-9.
18. van Schaik INV, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12: 325-34.
19. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, Kaneko H, Yamashina M, Kato Y, Orii T. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11: 152-8.
20. Masson PL. Elimination of infectious antigens and increase of IgG calabolism as possible modes of action of IVIg. J Autoimmunity 1993; 6: 683-9.
21. Ruiz-de-Souza V, Carreno MP, Kaveri SV, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG intravenous immunoglobulin. Eur J Immunol 1995; 25: 1267-73.
22. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71: 372-6.
23. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.
24. Rondeau E, Fournier A, Kanfer, A, Sraer JD. Polyvalent immunoglobulins in sensitised renal transplant recipients. Nephrol Dial Transplant 1991; (letter) 6: 675-6.
25. Peraldi MN, Akposso K, Haymann JP, Flahaut A, Marlin C, Rondeau E, Sraer JD. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996; 62: 1670-3.
26. Bunchman TE, Parekh RS, Kershaw DB, Smoyer WE, Flynn JT, Valentini RP, Sedman AB. Beneficial effect of sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clin Transplant 1997; 11: 604-7.
27. Latremouille C, Haeffner-Cavaillon N, Goussef N, Mandet C, Hinglais N, Bruneval P, Bariety J, Carpentier A, Glotz D. Normal human polyclonal immunoglobulins for intravenous use significantly delay hyperacute xenograft rejection. Transplant Proc 1994; 26: 1285.
28. Schussler O, Lantoine F, Devynck MA, Glotz D, David-Dufilho M. Human Immunoglobulins inhibit thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells. J Biol Chem 1996; 271: 26473-6.